6c85418b25
- Source: inbox/queue/2026-04-28-glp1-managed-access-operating-systems-payer-infrastructure.md - Domain: health - Claims: 2, Entities: 2 - Enrichments: 4 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
33 lines
No EOL
1.1 KiB
Markdown
33 lines
No EOL
1.1 KiB
Markdown
# Evernorth EncircleRx
|
|
|
|
**Type:** Managed-access program (PBM infrastructure)
|
|
**Parent:** Evernorth (Cigna)
|
|
**Domain:** GLP-1 utilization management
|
|
**Status:** Active
|
|
|
|
## Overview
|
|
|
|
Evernorth EncircleRx is a managed-access operating system for GLP-1 receptor agonists, managing utilization and cost across 9 million enrolled lives as of 2026.
|
|
|
|
## Program Structure
|
|
|
|
**Cost containment mechanisms:**
|
|
- 15% cost cap guarantee
|
|
- 3:1 savings guarantee (alternative structure)
|
|
- $200 copay cap on Wegovy and Zepbound (added 2025)
|
|
|
|
**Operational scale:**
|
|
- 9 million enrolled lives
|
|
- ~$200 million saved since 2024
|
|
|
|
## Strategic Context
|
|
|
|
EncircleRx represents Evernorth's response to GLP-1 fiscal pressure (10x PMPM increase 2023-2024) by building multi-layer infrastructure beyond traditional formulary management. The program competes with:
|
|
- Optum Rx Weight Engage (UHC)
|
|
- Manufacturer direct-to-employer channels (Lilly Employer Connect, Novo Nordisk DTE)
|
|
|
|
## Timeline
|
|
|
|
- **2024** — EncircleRx launched
|
|
- **2025** — Added $200 copay cap on Wegovy and Zepbound
|
|
- **2026** — Managing 9M lives, ~$200M cumulative savings reported |